Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

Contributed by: Business Wire

Logo

Tags

Science

Other Science

Biotechnology

Research

Pharmaceutical

Oncology

Health

Clinical Trials

Agreement with Neurocrine Biosciences

More Like This

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform

Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023

PR Newswire associated0

NeoMab Fully Human Antibody Discovery Platform: A New Flexible Mouse Purchase Model Leading a New Trend in Antibody Drug Development